Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: ) announced today that the followers clinical and preclinical
abstracts are expected to be the topic of unwritten or posting presentations at
the Annual Meeting of the American Association for Cancer Research (AACR),
being held April 12-16, 2008 in San Diego: -- "Dendritic and Deoxythymidine Monophosphate cell mathematical functions in patients with metastatic hormone-
refractory prostate gland gland malignant neoplastic disease treated with GVAX immunotherapy for prostate
malignant neoplastic disease and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session)
- Oral presentation scheduled for Monday, April 14, 2008 at 1:25 p.m. -- "CTLA-4 encirclement for internal secretion refractory prostate gland cancer: dose-dependent
induction of CD8+ Deoxythymidine Monophosphate cell activation and clinical responses" (Abstract
#2539, Clinical Immunotherapy Session) - Oral presentation scheduled
for Monday, April 14, 2008 at 1:40 p.m. -- "Increased doses of an anti-CD30 antibody, MDX-060, consequences in
drawn-out patterned advance free endurance in topics with CD30 positive
lymphoma" (Abstract #5525, Phase 2 and 3 Clinical Trials 3: Blood,
Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for
Wednesday, April 16, 2008 at 8:00 a.m. -- "Preclinical development of anti B7-H4 curative antibodies"
(Abstract #4986, Developmental Immunotherapy Session) - Oral
presentation scheduled for Tuesday, April 15, 2008 at 2:25 p.m. -- "Human antibody conjugate solutions of possible public utility for prostate gland cancer
therapy: a comparing of MGBA conjugate solutions with antibodies targeting a
cell surface mark (prostate-specific membrane antigen) and an extra-
cellular mark (Mindin/RG1)" (Abstract #4062, Immunoconjugates,
Peptides, and Protein Therapeutics Session) - Poster session scheduled
for Tuesday, April 15, 2008 at 8:00 a.m. -- "Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate"
(Abstract #4061, Immunoconjugates, Peptides, and Protein Therapeutics
Session) - Poster session scheduled for Tuesday, April 15, 2008 at 8:00
a.m. -- "Mechanism of activation of a human anti-CD70 antibody-MGBA conjugate
and efficaciousness in a bare rat theoretical account of nephritic carcinoma" (Abstract #4057,
Immunoconjugates, Peptides, and Protein Therapeutics Session) - Poster
session scheduled for Tuesday, April 15, 2008 at 8:00 a.m. -- "Ptk7 as a direct and tumour stroma mark in multiple solid
malignancies" (Abstract #1526, Targets and Screening Approaches
Session) - Poster session scheduled for Sunday, April 13, 2008 at 1:00
p.m. Abstracts and information about the AACR and its Annual Meeting may be
found at . About Medarex Medarex is a biopharmaceutical company focused on the discovery,
development and possible commercialisation of fully human antibody-based
therapeutics to handle life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune upsets and infective diseases. Medarex
applies its UltiMAb(R) engineering and merchandise development and clinical
manufacturing experience to generate, support and potentially commercialize
a wide scope of fully human antibody merchandise campaigners for itself and its
partners. More than 40 of these curative merchandise campaigners derived from
Medarex engineering are in human clinical testing or have got had INDs submitted
for such as trials, with seven of the most advanced merchandise candidates
currently in Phase 3 clinical trials or the topic of regulatory
applications for selling authorization. Medarex is committed to building
value by developing a diverse grapevine of antibody merchandises to turn to the
world's unmet healthcare needs. For more than information about Medarex, visit
its website at . Medarex(R), the Medarex logotype and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.